Search

Displaying results 6641 - 6650 of 9705 in total
  1. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    It is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA). … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

  2. Drug

    XL418

    go.drugbank.com/drugs/DB05204
    Investigational

    XL418 is a novel anticancer compound.

  3. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

  4. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.

  5. Drug

    Teglarinad chloride

    go.drugbank.com/drugs/DB05217
    Investigational

    GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. … In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond.

  6. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors. … Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing.

  7. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.

  8. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  9. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

  10. Drug

    Silver sulfadiazine

    go.drugbank.com/drugs/DB05245
    ApprovedInvestigationalVet approved

    Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

    Products: DERMOPLATA CREMA AL 1%, SULFADIAZINA CREMA AL 1 %